Dosing and uses of Rociletinib
Non-small Cell Lung Cancer (NSCLC)
Epidermal growth factor receptor (EGFR) inhibitor for treatment of patients with mutant EGFR NSCLC who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation
Pediatric dosage forms and strengths
Safety and efficacy not established
Pharmacology of Rociletinib
Mechanism of action
Targeted covalent (irreversible) epidermal growth factor receptor (EGFR) inhibitor
